Investors got a reminder of the capabilities of Palantir Technologies' (NYSE: PLTR) products, helping to reinforce the bull case for the stock. Palantir came to market in late 2020 to great enthusiasm, based largely on the reputation of its technology. The data-analytics provider is credited with helping the Pentagon find Osama bin Laden and with flagging the Bernie Madoff Ponzi scheme.
Yahoo Finance Live’s Rachelle Akuffo breaks down the expectations for Apple, Amazon, and Alphabet earnings.
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though its clinical trials have (so far) shed little light on the issue. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam, the market reacted quite negatively to the release of new data that management spun as being positive.
When Cathie Wood speaks, people listen. The chief executive of Ark Investment Management has had a far-from-perfect record when it comes to her investment choices -- not to mention not exactly flattering feedback from CNBC's Jim Cramer. When asked what stock Wood would choose she won a million dollar lottery and was forced to choose a stock for ten years, Wood's pick was just as disruptive as her reputation.
Shares of Coinbase (NASDAQ: COIN) have gotten crushed since hitting public markets, but the business is in better shape than you might think. There's billions of dollars in cash on the balance sheet, and there are growing revenue sources from USDC and Ethereum (CRYPTO: ETH) staking.
For the third day in a row, Tesla (NASDAQ: TSLA) stock is riding higher -- up 4.3% as of 10:10 a.m. ET. The Federal Reserve's decision to raise interest rates only 25 basis points yesterday is probably part of the reason for that -- indeed, growth stocks in general seem happy to run today, with the entire Nasdaq up nearly 2%. Tesla's plan to cut the prices of its electric cars, you see -- not just in the U.S., but in China as well -- is having its intended effect of stoking consumer demand.
The Nasdaq Composite dipped into a bear market last year, and the tech-heavy index is still 28% off its high. Investors often overreact to good and bad news, so stocks tend to rise too high during bull markets and fall too far during bear markets. Warren Buffett hinted at that quirk of human nature when he said, "Be fearful when others are greedy, and be greedy when others are fearful."
A short squeeze occurs when short-sellers rush to cover their positions on a stock. The sudden rush of buying can quickly push a stock price higher. After a tough market year in 2022, some stocks have built up large short-seller followings, potentially priming the pump for a new wave of short squeezes.
Despite a dismal performance in 2022, shares of all-digital bank SoFi Technologies (NASDAQ: SOFI) climbed 50.3% in January. There are lots of reasons for the run-up, not least of which were a better-than-expected performance during the fourth quarter of 2022 and an improved outlook. Will the big gains SoFi made in January fizzle out in February, or is the stock at the beginning of a much longer bull run?
Top health insurance company Humana (NYSE: HUM) wasn't necessarily tops with investors on Wednesday. After reporting its latest set of quarterly figures, the company's share price bumped slightly higher, by 0.3%, which wasn't high enough to beat the S&P 500 index's more than 1% increase. It's not that Humana's results for the fourth quarter 2022 were bad or uninspiring; it's just that they didn't excel.
Yahoo Finance Live’s Julie Hyman breaks down oil earnings.
Shares of apparel company Hanesbrands (NYSE: HBI) dropped like a rock on Thursday after the company provided lackluster financial guidance and announced some substantial pivots to management's priorities. As of 11:40 a.m. ET, Hanesbrands stock was down 23% -- particularly painful, considering the market is soaring today. On one hand, fourth-quarter revenue of $1.47 billion beat guidance from Hanesbrands' management.
Change doesn't have to be bad.
Dividend investors should consider loading up on these stocks as this could be a good year for both of their businesses.
Dividend stocks are a great way to mitigate downside risk, hedge against inflation, and generate reliable levels of passive income. Closed-end funds, real estate investment trusts (REITs), and some actively managed diversified holding companies are purpose-built to return an outsize portion of cash flows to shareholders via regular distributions. Arbor Realty Trust (NYSE: ABR) is a REIT with a current annualized yield of 10.75%.
Carvana stock has crashed back to Earth after a massive run, and these three indicators show just how bad things are.
Pfizer (NYSE: PFE) enjoyed a record year in 2022. The big drugmaker's revenue topped $100 billion. Its earnings per share soared 42% to $5.47, which translates to nearly $31.4 billion in profits. Both top- and bottom-line numbers set all-time highs.
Archer-Daniels-Midland, Agilent Technologies, Republic Services, Deere and Cardinal Health have been highlighted in this Screen of The Week article.
Did you know that if a company were to increase its dividends by 5% per year, it would take 14 years for its payouts to double? A couple of stocks with the most aggressive dividend growth records you can invest in today are UnitedHealth Group (NYSE: UNH) and Broadcom (NASDAQ: AVGO). Health insurance giant UnitedHealth Group may not strike income investors as an ideal dividend stock to buy, as it yields just under 1.4%, which is below the S&P 500's current average yield of 1.7%.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $317.27, marking a -1.8% move from the previous day.